Skip to content

Author

J. Dixon-Douglas

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Breast cancer immunogenicity as a spectrum: evolving concepts and therapeutic implications

Immunotherapy has revolutionized the therapeutic landscape for many cancers, but its application in solid tumors has lagged. There is now evidence that immunotherapy can improve outcomes in triple-negative breast cancer, but hormone receptor–positive (HR+) breast cancer has traditionally been considered immunologically...

J. Kay, J. Dixon-Douglas, M. Harris et al. · 0 citations
Open access Aug 2026

Rb-driven transcription limits its tumour-suppressive effects in breast cancer

The retinoblastoma protein (Rb) is a tumour suppressor best known for repressing E2F transcription factors and halting cell cycle progression1. In hormone receptor-positive (HR+) breast cancer, CDK4/6 inhibitors activate Rb by preventing its phosphorylation, forming a key component of current endocrine therapy regimens...

April C. Watt, Antonio Ahn, Catherine Blyth et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.